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Abstract 
Over the past several years, treatment of infectious diseases and 
immunization has undergone a paradigm shift. Stemming from 
the nanobiotechnology research, not only a large number of 
disease-specific biologicals have been developed, but also 
enormous efforts have been made to effectively deliver these 
biologicals. Niosomes are vesicular systems prepared from self-
assembly of hydrated non-ionic surfactants. Opinions of the 
usefulness of niosomes in delivery of proteins and biologicals 
range from unsubstantiated optimism to undeserved pessimism. 
This article reviews the current deepening and widening of 
interest of niosomes in many scientific disciplines, and their 
application in medicine particularly for the delivery of proteins 
(insulin, cyclosporine, bacitracin, trypsin), vaccines and antigens 
(bovine serum albumin, antigen tetanus toxoid, haemagglutinin). 
This article also presents an overview of techniques of noisome 
preparation, characterization of niosomes and their applications. 
Keywords: Niosomes, Proteins, Biologicals, Vaccines, Oral 
delivery 
 
 
Introduction 
Recent advances in the fields of genetic research 
and biotechnology have resulted in endorsement 
of biologicals such as proteins and vaccines as a 
major class of therapeutic agents. Biologicals 
against debilitating diseases have proven 
remarkable in prevention of these diseases and 
have contributed significantly to an increase in 
life expectancy. Administration of these agents in 
their active state has been a formidable challenge 
to the biotechnological as well as pharmaceutical 
industries. Drug associated challenges such as 
poor bioavailability, suitable route of drug 
delivery, physical and chemical instability, and 
potentially serious side effects of these  
 
 
 
 
biologicals are some potential limitations on their 
successful formulation development. The 
nanobiotechnology i.e., combination of 
nanotechnology and biotechnology has proposed 
a new approach as a solution to their formulation 
problem in the form of niosomes [1, 2].  
 
Protein delivery 
DNA recombinant technology has made possible 
the large-scale production of these proteins, 
however, the ability to deliver these compounds 
systemically using convenient and effective 
delivery systems remains a challenge. Although 
the oral route is the most convenient and popular, 
protein delivery by this route is limited by low 
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and erratic absorption, mainly due to degradation 
by proteolytic enzymes and poor permeability of 
the gastrointestinal mucosa. Many of these 
proteins are unable to accomplish their full range 
of therapeutic benefits when administered 
through the alternative routes due to presence of 
protease. There is a significant need for novel 
delivery systems that would retain the efficiency 
of these agents and deliver the drug at a 
controlled rate with prolonged biological activity 
[3]. When developing a novel delivery system, 
the biophysical, biochemical, and physiological 
characteristics of protein, as well as 
pharmacokinetics and pharmacodynamics are 
important to consider [4]. 
 
Vaccine delivery 
Vaccination technology in controlling infectious 
diseases has made remarkable contributions to 
public health and quality of life, because it has 
been proven that vaccines have saved more lives 
than drugs [5]. Presently most vaccines for 
protection against both systemic and superficial 
pathogens are administered parentrally in order to 
avoid antigen degradation in the gut. Oral 
delivery of vaccines is attractive, since this offers 
a number of inherent advantages over the 
parenteral route, including increased patient 
compliance, ease and convenience of 
administration, reduced costs and minimal side 
effects. Most of the oral vaccines so far are based 
on either live attenuated organisms or employ 
synthetic peptides, proteins and polysaccarides. 
Due to their susceptibility to degradation during 
gastric and intestinal passage, these compounds 
require more sophisticated delivery systems. New 
vaccines based on recombinant proteins and 
DNA, are safer than traditional vaccines, but they 
are less immunogenic. Therefore, there is an 
urgent need for the development of potent and 
safe adjuvants and delivery systems that can be 
used with new generation of vaccines. 
 
Vesicular systems: Niosomes 
Among vesicular systems, opinions of the 
usefulness of niosomes in various 
biotechnological applications range from 
unsubstantiated optimism to undeserved 
pessimism. Niosomes offer an attractive mode of 
delivery for biological agents belonging to the 
class of proteins and vaccines, since they are able 
to overcome some inherent problems associated 
with these molecules. These problems include 
suitable route of delivery, physical as well as 
chemical instability, poor bioavailability, and 
potent side effects. Niosomes are organized non-
ionic surfactant based vesicles formed from the 
self-assembly of non-ionic amphiphiles in 
aqueous media resulting in closed bilayer 
structures (Fig. 1). The assembly into closed 
bilayers is rarely spontaneous and usually 
involves some input of energy such as physical 
agitation or heat [6]. The result is an assembly in 
which the hydrophilic head groups enjoy 
maximum contact with the aqueous solvent and 
hydrophobic parts of the molecule are shielded 
from the same. Hydrophilic drugs can be 
encapsulated in the internal aqueous compartment 
while lipophilic and hydrophobic drugs can be 
associated with the bilayers of the vesicles. A 
large number of non-ionic surfactants with 
varying HLB have been used to prepare vesicles 
viz. polyglycerol alkylethers, glucosyl dialkyl 
ethers, crown ethers, polyoxyethylene ethers and 
esters, briz and a series of spans and tweens [7]. 
Cholesterol is one of the vital components and 
provides rigidity to the bilayer by making 
vesicles less leaky [8]. Both cholesterol content 
and HLB of the surfactant tends to affect the 
important vesicular properties, which should be 
optimized in the terms of better therapeutic 
efficacy and for the use of vesicles in 
pharmaceutical application. Thermodynamically 
stable vesicles are formed only in the presence of 
proper mixture of surfactants and charge inducing 
agents, which helps in electrostatic stabilization 
of vesicles. Such charge inducing agents include 
stearylamine, dicetyl phosphate and 
diacylglycerol. The low cost of ingredients, ease 
of large scale production, greater stability and 
resultant ease of storage of niosomes has lead to 
the exploitation of these systems as alternative to 
other micro- and nano- encapsulation 
technologies. Additionally, niosomes are  
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biocompatible, non-immunogenic, biodegradable,  
non-toxic and capable of site specific delivery. 
                               .         
Preparation of Niosomes 
The most commonly used method for preparation 
of protein or vaccine loaded niosomes identified 
in the literature are summarized as follows. 
 
Multilamellar vesicles (MLVs) - Film hydration 
is the simplest method and is widely used. In this 
method, the surfactants are dissolved in an 
organic solvent in a round-bottomed flask and 
 a thin surfactant film is allowed to formed on the 
inside wall of the flask by removal of the organic 
solvent. An aqueous buffer containing drug is 
then added and the dry film is hydrated above the 
transition temperature (Tc) of the surfactant. 
Shaking (by hand or by vortex mixer) yields a 
dispersion of MLV. Dehydration-rehydration is 
another technique to produce MLVs with high 
entrapment efficiencies [9]. 
 
Large Unilamellar Vesicles (LUVs) - LUVs are 
prepared via reverse phase evaporation method 
wherein surfactants and cholesterol are dissolved 
in an organic solvent. The aqueous phase is added 
to the organic phase and the mixture is sonicated 
in order to form an emulsion, followed by slow  
 
 
 
 
Fig. 1 Schematic representation of drug loaded niosome  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
removal of the organic phase. LUVs with 
relatively high entrapped aqueous volume are 
also produced by solvent injection technique 
where solutions of surfactant in solvents with 
high vapor pressure are injected into excess 
aqueous phase under reduced pressure. 
 
Small Unilamellar Vesicles (SUVs) - MLV 
dispersions are converted into SUVs by 
application of external energy by either 
sonication using bath sonicator or a probe 
sonicator, or by high pressure homogenization 
using microfluidizer or by extrusion under high 
pressure using French pressure cell [9]. During 
application of energy the MLV structure is 
broken down and SUVs with a high radius of 
curvature are formed.  
 
Characterization of Niosomes  
Niosomes are characterized chiefly for their size, 
morphology, charge, rigidity, homogeneity and 
drug loading capacity. 
 
Vesicle size and morphology- Niosome size can 
range from around 20 nm to around 50 µm. 
Several techniques can be used to determine 
vesicle size and size distribution. Large 
niosomes, those with diameters over 1 µm, can be 
 
 
16
Shilpa et al. International Journal of Drug Delivery 3 (2011) 14-24 
 
adequately measured by light microscopy and the 
Coulter counter. Light microscopy offers the 
possibility of collecting information on particle 
shape, whereas the volume distribution of 
niosomes (>1 µm) in dispersions can be 
determined with Coulter counter. For vesicles in 
the submicron range, size can be assessed by 
electron microscopic analysis or by light 
scattering techniques. Electron microscopic 
analysis such as transmission electron  
microscopy or freeze-fracture techniques not only 
analyze niosome size, but also analyze number of 
bilayers. Further, scanning electron microscopy, 
atomic force microscopy  and cryo transmission 
electron microscopy are also used to study the 
shape and surface characteristics of the niosomes. 
  
Vesicle charge - The vesicle surface charge can 
play an important role in the behavior of 
niosomes in vivo and in vivo. In general, charged 
niosomes are more stable against aggregation and 
fusion than uncharged vesicles. In order to obtain 
an estimate of the surface potential, the zeta 
potential of individual niosomes can be measured 
by microelectrophoresis.  
An alternative approach is the use of pH-sensitive 
fluorophores. More recently, dynamic light 
scattering have been used to measure the zeta 
potential of niosomes.  
 
Bilayer Rigidity and Homogeneity- The 
biodistribution and biodegradation of niosomes 
are influenced by rigidity of the bilayer. 
Inhomogeneity can occur both within niosome 
structures themselves and between niosomes in 
dispersion and could be identified via. p-NMR, 
differential scanning calorimetry (DSC) and 
fourier transform-infra red spectroscopy (FT-IR) 
techniques. Recently, fluorescence resonance 
energy transfer (FRET) was used to obtain deeper 
insight about the shape, size and structure of the 
niosomes [10].  
Niosomal drug loading and encapsulation 
efficiency- To determine drug loading and 
encapsulation efficiency, the niosomal aqueous 
suspension was ultracentrifuged, supernatant was 
removed and sediment was washed twice with 
distilled water in order to remove the adsorbed 
drug. The niosomal recovery was calculated as:  
 
The entrapment efficiency (EE) was then 
calculated using formula:  
 
 
The drug loading was calculated as: 
 
 
Niosomal drug release - Recently, FRET was 
used to monitor release of encapsulated matters in 
niosomes by using separate niosomal suspensions 
incorporating donor and acceptor [10]. The 
simplest method to determine in vitro release 
kinetics of the loaded drug is by incubating a 
known quantity of drug loaded niosomes in a 
buffer of suitable pH at 37°C with continuous 
stirring, withdrawing samples periodically and 
analyzed the amount of drug by suitable 
analytical technique. Dialysis bags or dialysis 
membranes are commonly used to minimize 
interference. 
 
Applications 
Pulmonary delivery  
Although inhaled glucocorticosteroid such as 
beclomethasone dipropionate (BDP) is the most 
effective therapy available for patients with 
asthma but the role of this drug in the 
management of chronic obstructive pulmonary 
disease (COPD) is less certain due to poor 
permeation through the hydrophilic mucus in 
order to reach the glucocorticoid receptor, located 
in the cytoplasm of bronchial epithelial cells. 
Pulmonary delivery of BDP through polysorbate 
20 niosomes offers the advantages of sustained 
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delivery, an improved mucus permeation, 
targeted drug delivery and amplified therapeutic 
effect [11]. The clinical efficacy of therapeutic 
aerosols depends on the aerodynamic size 
distribution of the aerosol and the drug output 
from the nebulizer. The vesicular dispersions 
show the aerodynamic diameter comparable with 
the commercial product. In all conditions of 
nebulization, the niosomal dispersion seems to 
release a greater amount of BDP on filters (37%) 
with respect to BDP surfactant solution (25%) 
and BDP commercial product (35%). The results 
obtained by either TurboBoy nebulizer or Clenny 
nebulizer were similar. The rheology of the 
niosomal BDP formulation is also comparable to 
that of commercial product. In addition the non-
ionic surfactant vesicles remarkably increase the 
permeation rate of BDP through the model 
mucosal barrier thus offering a better targeting of 
corticosteroids in the treatment of COPD.  
 
Oral delivery  
The delivery of biopharmaceuticals to the 
systemic circulation through oral administration 
is hindered by numerous barriers, including pH 
gradients, proteolytic enzymes and low epithelial 
permeability. The oral delivery of recombinant 
human insulin using niosomal formulations was 
demonstrated by a study involving 
polyoxyethylene alkyl ethers based niosomes. 
Entrapment of insulin in bilayer structure of 
niosomes protected it against proteolytic activity 
of α-chymotrypsin, trypsin and pepsin in vitro. 
Significantly higher protection activity was seen 
in Brij 92/cholesterol (7:3 molar ratios) in which 
only 26.3±3.98% of entrapped insulin was 
released during 24 h in simulated intestinal fluid 
(SIF) [12]. The kinetic of drug release is 
described by Baker and Lonsdale equation 
indicating diffusion based delivery mechanism. It 
thus appears that niosomes could be developed as 
sustained release oral dosage forms for delivery 
of peptides and proteins such as insulin. Yoshida 
et al investigated oral delivery of 9-
desglycinamide-8-arginine vasopressin entrapped 
in niosomes in an in vitro intestinal loop model 
and reported that stability of peptide increased 
significantly. Manosroi et al., had demonstrated 
the enhanced entrapment of charged peptide 
drugs, bacitracin, insulin and bovine serum 
albumin in niosomes by modifying the vesicular 
charge compositions. Cationic, anionic and 
neutral niosomes were prepared from sorbitan 
monostearate (Span 60) or polyoxyethylene 
sorbitan monostearate (Tween 60), cholesterol 
(CHL), dimethyldioctadecylammonium bromide 
(DDAB) and/or dicetyl phosphate (DP). Anionic 
niosomes were oligolamellar membrane structure 
with the sizes of 40-60 nm whereas neutral 
niosomes and cationic niosomes showed the sizes 
of 0.1-1.3 µm and 100-150 nm, respectively. The 
highest entrapment efficiency of bacitracin, 
bovine serum albumin and insulin at 90.88, 72.94 
and 87.15 was observed in anionic, neutral and 
cationic niosomes, respectively [13]. The results 
suggested the appropriate niosomal formulation 
to entrap the peptides with different charges and 
polarity for pharmaceutical application. In one of 
the first studies of its kind sucrose ester niosomes 
loaded with ovalbumin were found to cause a 
modest but significant increase in the level of 
specific antibodies after oral administration  [14]. 
 
Vaginal delivery  
Vaginal delivery of insulin niosomes reportedly 
prepared from Span 40 and Span 60 and nearly 
250 nm in size were found to have enhanced 
hypoglycemic effects compared with 
subcutaneous administration of insulin solution to 
rats. Compared with subcutaneous administration 
of insulin solution, the relative pharmacological 
bioavailability and the relative bioavailability of 
insulin-Span 60 vesicles group were 8.43% and 
9.61%, and insulin-Span 40 niosomes were 
9.11% and 10.03% (p > 0.05). The results 
indicates insulin-Span 60, Span 40 niosomes had 
an enhancing effect on vaginal delivery of insulin 
[15]. Although the factors controlling the process 
for penetration of a portion of vaginally 
administrated niosomes into bloodstream from 
vaginal tract were not fully understood but the 
authors postulated that after encapsulation in 
niosomes, insulin became an active and 
efficiently therapeutic agent when administrated 
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vaginally and niosomes might be a good carrier 
for vaginal delivery of protein drugs. 
 
Brain delivery  
The vasoactive intestinal peptide (VIP) is a 
neuropeptide of the glucagon-secretin family  
with a widespread distribution in both the central 
and peripheral nervous system. It exerts diverse 
peripheral biological functions, such as anti-
inflammatory and immunomodulatory effects, 
regulation of cell growth and differentiation and 
participation in the development of neural tissue 
[16]. VIP have interesting applications in the 
treatment of Alzheimer’s disease. However, like 
most endogenous peptides, its potential 
therapeutic applications are limited by its failure 
to cross the blood–brain barrier (BBB) and by its 
rapid elimination after intravenous 
administration. The association of VIP with 
glucose-bearing niosomes allowed a significantly 
higher VIP brain uptake compared to control 
niosomes (up to 86%, 5 min after treatment). 
Brain distribution of intact VIP after injection of 
glucose-bearing niosomes, indicated that 
radioactivity was preferentially located in the 
posterior and the anterior parts of the brain [17]. 
Niosomes believed to curtail enzyme-induced 
inactivation of VIP, and the association of VIP 
with glucose-bearing niosomes also facilitates 
transport of VIP through BBB, leading to 
enhanced brain uptake. In conclusion, the study 
demonstrated that the administration of systemic 
glucose-bearing niosomal vesicles encapsulating 
VIP could deliver intact VIP to specific brain 
areas. Therefore, glucose-bearing vesicles 
represent a novel tool to deliver drugs across the 
BBB. 
 
Transdermal delivery  
Cyclosporin A glyceryl dilaurate:C16EO10: 
cholesterol niosomes increased the uptake of drug 
into deeper skin strata [18]. The niosomal vehicle 
also demonstrated deposition of alpha-interferon 
into pilosebaceous units of the hamster ear model 
[19]. The enhanced delivery of niosome 
encapsulated drugs through the stratum corneum 
has been observed  [20, 21] and it therefore 
remains to elucidate the mechanism of this 
delivery. Small (100 nm) vesicular structures 
have been observed between the first and second 
layer of human corneocytes 48 h after incubation 
with dodecyl alcohol polyoxyethylene ether 
niosomes [22]. The same study reports the 
presence of niosomes in the deeper seemingly 
inaccessible areas of the skin and concludes that 
there was a reorganisation of the niosome 
membrane into individual monomers which on 
arriving at these deeper layers reformed into 
niosomes [22]. Based on the above studies, it 
does appear that transdermal delivery of protein 
and biologicals with niosomes appears promising 
and would require that the dose be applied in high 
concentration and within niosomes prepared from 
low phase transition surfactant mixtures. The 
mechanism of niosome penetration between 
bilayers appears to lie between destruction: 
reconstruction hypothesis [22] and the highly 
flexible hypothesis [23]. 
Vesicles with biological activity or with a 
targeting function in addition to carrier properties 
will have an added advantage. Aspasomes, 
vesicles prepared from ascorbyl palmitate, having 
antioxidant property also possess skin permeation 
enhancing property. Ascorbyl palmitate formed 
vesicles in combination with cholesterol and a 
negatively charged lipid (dicetyl phosphate) by 
film hydration method. The studies revealed that 
the antioxidant potency of ascorbyl moiety was 
better after converting ascorbyl palmitate into 
vesicles (Aspasomes). Further, azidothymidine 
(AZT) aspasomes showed significantly higher 
transdermal permeation compared to aspasomes-
AZT aqueous dispersion and AZT-solution [24]. 
Thus, aspasomes may find applications as 
transdermal delivery of proteins particularly in 
disorders implicated with reactive oxygen 
species. 
 
Systemic delivery  
Polyethylene glycol (PEG) modified cationic 
niosomes were used to improve the stability and 
cellular delivery of oligonucleotides (OND). 
PEGylated cationic niosomes, composed of DC-
Chol, PEG2000-DSPE and Span, offer some 
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advantages as gene carriers. Complexes of 
PEGylated cationic niosomes and OND showed a 
neutral zeta potential with particle size about 300 
nm. PEG-modification not only increased the 
particle stability in serum but also enhanced the 
nuclease resistance of the loaded gene drug. 
Compared with cationic niosomes, complexation 
of PEGylated cationic niosomes with OND 
enhanced the cellular uptake of OND in serum 
[25]. The presence of PEG coated on the cationic 
niosomes not only contributes to the neutral zeta 
potential but also prevents serum proteins and 
nucleases from approaching the cargo. Thus, in 
terms of their stable physiochemical properties in 
storage and physiological environment, as well as 
low-cost and widely available materials, 
PEGylated cationic niosomes are promising drug 
delivery systems for improved OND potency in 
vivo. 
In an another study, the preparation, 
characterization and activity of non-phospholipid 
vesicles based on polyglycerol alkyl ethers and 
on sorbitan monoalkyl ethers for the transport of 
aminoacid based molecules, such as trypsin, 
bovine basic pancreatic inhibitor and polylysine 
rich peptides derived from the herpes simplex 
virus type 1 (HSV-1) glycoprotein B were 
described [26]. Niosomes containing the 
indicated model drugs have shown to be more 
stable in term of size with respect to liposomes. 
In addition, niosomes, (i) are able to encapsulate 
the model drugs over 49%, (ii) are characterized 
by dimensions compatible with 
applications on the mucous membrane, (iii) 
remain stable in size for at least 3 months and (iv) 
can release the model drug (after a slight lag 
time) in a controlled fashion as compared to that 
of the corresponding free solution. 
 
Vaccine and antigen delivery  
A number of surfactants have documented 
immunostimulatory properties [27] and have been 
used as vaccine adjuvants. The adjuvanticity of 
niosomes prepared from 1-mono-palmitoyl 
glycerol, cholesterol, dicetyl phosphate-5:4:1 has 
been demonstrated in mice, on subcutaneous 
administration of ovalbumin or a synthetic 
peptide containing a known T-cell epitope [28] 
and bovine serum albumin [29]. The 
intraperitoneal administration of same niosome 
vesicle has also been shown to act as a vaccine 
adjuvant to severe combined immunodeficiency 
mice reconstituted with peripheral blood 
lymphocytes (PBL-SCID mice) [30]. 
A vesicle in water in oil (v:w:o) emulsion [31] 
prepared from Span 80 and cotton seed oil has 
been evaluated as an immunological adjuvant 
using the model antigen tetanus toxoid [32] . An 
increased secondary response (level of IgG1) was 
observed when the v:w:o formulation was 
administered by the intramuscular route in 
comparison with the vesicle formulation and the 
free antigen. Nonionic surfactant vesicles were 
also reported for nasal mucosal delivery of viral 
influenza vaccine antigen.  
Bovine serum albumin (BSA) and 
haemagglutinin (HA) loaded niosomes have been 
formulated as multi-component organogels using 
the non-ionic surfactant sorbitan monostearate as 
gelator [33]. The complex gels were prepared by 
the addition of a hot aqueous niosome suspension 
to the organic solution of the gelator; a vesicle-in-
water-in-oil (v/w/o) emulsion was produced 
which cools to an opaque, semi-solid, 
thermoreversible v/w/o gel [33]. Microscopy 
revealed that the microstructure consists of a 
tubular network of surfactant aggregates in the 
organic medium and the niosome suspension 
being dispersed in these surfactant tubules [33]. 
In vivo, a depot effect was observed following 
intramuscular administration of the gel containing 
the entrapped bovine serum albumin, cleared 
from the injection site over a period of days. The 
relatively short-lived nature of the depot was 
thought to arise due to interactions between the 
gel and the local interstitial fluid which results in 
gel disintegration in situ. Thus, the niosomes 
containing antigens are believed to be released 
from the organic gel. Immunogenicity studies 
showed that the v/w/o gel as well as one of the 
controls, the water-in-oil (w/o) gel, possess 
immunoadjuvant properties and enhance the 
primary and secondary antibody titres (of total 
IgG, IgG1, IgG2a and IgG2b) to haemagglutinin 
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antigen. As far as humoral immunity is 
concerned, the w/o gel showed stronger 
immunoadjuvant properties compared to the  
 Table:1 Proteins and biologicals formulated as niosomes. 
 
Drug Administration route Components Preparation method Application 
Proteins and Peptides 
Beclomethasone Pulmonary Polysorbate 20, cholesterol Film hydration 
Sustained and targeted 
delivery, increased 
mucus penetration 
Rh-Insulin Oral Polyoxyethylene alkyl ether, cholesterol, dicetylphosphate Modified handshaking method 
Protection against 
proteolysis, sustained 
release 
Bacitracin Oral  
Span 60/Tween 61, cholesterol, 
dimethyldioctadecylammonium 
bromide/or dicetyl phosphate 
Freeze dried empty liposome Increased entrapment 
Bovine serum albumin Oral 
Span 60/Tween 60, cholesterol, 
dimethyldioctadecylammonium 
bromide/ dicetyl phosphate 
Freeze dried empty liposome Increased entrapment 
9- desglycinamide, 8-arginine 
vasopressin Oral - Sonication 
Stabilization of peptide 
 
Insulin Vaginal Span 40 and Span 60 Phase evaporation with sonication 
Enhanced hypoglycemic 
effects 
Vasoactive intestinal peptide Brain N-Palmitoylglucosamine , Span 60, cholesterol, solulan C24 
Handshaking followed by 
sonication 
Significantly higher VIP 
brain uptake 
Cyclosporine A Transdermal 
glyceryl dilaurate/ 
cholesterol/polyoxyethylene-10-
stearyl ether 
- Target to pilosebaceous units 
α-interferon Transdermal Glyceryl dilaurate/ cholesterol/ polyoxyethylene-10-stearyl ether - 
Target to pilosebaceous 
units 
Azidothymidine Transdermal Aspasomes: ascorbyl palmitate, cholesterol, dicetyl phosphate 
Film hydration method with 
sonication Transdermal permeation 
Trypsin Systemic 
Polyglycero-6-oleate, sorbitan 
monolaurate, polyoxyethylene 
sorbitan monolaurate,  cholesterol 
Film hydration method Stabilization of drug, controlled release 
Bovine basic pancreatic 
inhibitor Systemic 
Polyglycero-6-oleate, sorbitan 
monolaurate, polyoxyethylene 
sorbitan monolaurate, cholesterol 
Film hydration method Stabilization of drug, controlled release 
Polylysine rich peptides Systemic 
Polyglycero-6-oleate, sorbitan 
monolaurate, polyoxyethylene 
sorbitan monolaurate, cholesterol 
Film hydration method Stabilization of drug, controlled release 
Oligonucleotide Systemic DC-Cholesterol, PEG 2000-DSPE and span - Enhanced cellular uptake 
Vaccines and antigens 
Ovalbumin Intragastric Sucrose esters, cholesterol and dicetyl phosphate Film hydration with sonication 
Significant increase in 
antibody titres 
Ovalbumin subcutaneous 1-mono-palmitoyl glycerol, cholesterol, dicetyl phosphate Dehydration-rehydration vaccine adjuvant 
T-cell epitope intraperitoneal 1-mono-palmitoyl glycerol, cholesterol, dicetyl phosphate Dehydration-rehydration vaccine adjuvant 
Antigen tetanus toxoid intramuscular Span 80 and cotton seed oil Dehydration-rehydration immunological adjuvant 
Viral influenza vaccine antigen Nasal mucosal Surfactant, cholesterol, dicetyl phosphate Dehydration-rehydration - 
Haemagglutinin Intramuscular Organogels,  sorbitan monostearate Vesicle-in-water-in-oil emulsion Immunoadjuvant 
DNA Vaccine Oral 
Span 60, cholesterol and 
stearylamine coated with a o-
palmitoyl mannan 
Reverse phase evaporation 
method 
Protection from 
enzymatic degradation, 
enhanced affinity 
towards antigen 
presenting cells of 
Peyer’s patches. 
 
 
v/w/o gel, being effective at a lower antigen dose 
i.e 0.1 µg haemagglutinin antigen. Thus, 
niosomes may offer many advantages over other 
adjuvants in terms of immunological selectivity, 
low toxicity and stability [33]. 
Recently, mannosylated niosomes as oral DNA 
vaccine carriers for the induction of humoral, 
cellular and mucosal immunity were described.  
Niosomes composed of span 60, cholesterol and 
stearylamine were prepared by reverse phase 
evaporation method and were coated with o-
palmitoyl mannan (OPM) in order to protect them 
from enzymatic degradation in the 
gastrointestinal tract and to enhance their affinity 
towards the antigen presenting cells of Peyer’s 
patches [34]. Presence of OPM coating improves 
the stability of niosomes in GI tract. Although, 
the serum anti-HBsAg titer obtained after oral 
administration of OPM coated niosomal 
formulations was less as compared to that elicited 
by naked DNA and pure HBsAg administered 
intramuscularly, but the mice were seroprotective 
within 2 weeks and antibody level far above the 
clinically protective limit for humans was 
achieved. Further, intramuscular naked DNA and 
recombinant HBsAg did not elicited sIgA titer in 
mucosal secretions that was induced by oral 
administration of OPM coated niosomes. 
Similarly, OPM coated niosomes produced 
humoral (both systemic and mucosal) and cellular 
immune response upon oral administration. The 
study signifies the potential of OPM coated 
niosomes as DNA vaccine carrier and adjuvant 
for effective oral immunization  [34]. 
 
Diagnostic imaging  
Apart from the use of niosomes as various drug 
carriers one report in the literature details the 
evaluation of these systems as diagnostic agents. 
C16C12G7 and C16G3 niosomes containing 
cholesterol and stearylamine encapsulating the 
radioopaque agent iopromide were found to 
concentrate in the kidneys on intravenous 
administration [35]. The presence of the positive 
charge on the niosome surface was found to be 
responsible for kidney targeting. C16G3 niosomes 
resulted in highest kidney iopromide 
concentration owing to less fluid bilayer than the 
C16C12G7 [35]. Although the niosome formulation 
enhanced the opacity of this contrast agent, poor 
encapsulation efficiency agent was a problem 
with this system and clinically relevant 
enhancement of opacity was not achieved in this 
study.  
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